Share

ACS CAN Comments on Draft FDA Guidance on Clinical Trial Diversity Plans

June 13, 2022

ACS CAN submitted comments to the U.S. Food and Drug Administration (FDA) on the Diversity Plans To Improve Enrollment of Participants From Underrepresented Racial and Ethnic Populations in Clinical Trials Draft Guidance for Industry.